Press Releases

Date	Title
10/15/21	Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
10/6/21	Vir Biotechnology to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Conference
9/30/21	Vir Biotechnology to Participate in the Guggenheim 2nd Annual Vaccine & Infectious Disease Day Conference
9/8/21	Vir Biotechnology to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
9/7/21	Vir Biotechnology to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
8/23/21	Vir Biotechnology Announces First Marketing Authorization for its First Commercial Product, Sotrovimab, Granted in Australia
8/5/21	Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2021 Financial Results
7/28/21	GSK and Vir Biotechnology Announce Joint Procurement Agreement with European Commission for COVID-19 Treatment, Sotrovimab
7/22/21	Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021
7/15/21	Vir Biotechnology Initiates Phase 2 Clinical Trial Evaluating the Combination of VIR-2218 and VIR-3434 as a Functional Cure Regimen for Chronic Hepatitis B Virus Infection

Vir - Investor Relations Menu